RESUMEN
The lentiviral vector is a promising tool for human gene therapy because of its ability to transduce genes into many cell types. However, one of the technical problems associated with the lentiviral vector is that lentiviral titers in current production systems are relatively low compared with the other viral vectors. In this study, we provide genetic evidence that the attachment of heterologous myristoylation (myr) signals on the amino-terminus of human immunodeficiency virus type 1 Pr55(Gag) (Gag) can increase the viral yield up to 10-fold, leading to the enhancement of gene transduction in many cell lines. The myr signal Gag constructs behaved similarly to the wild-type Gag in targeting to detergent-resistant membrane compartments, Vps4-dependence for viral budding, and virion morphology. However, the myr signal Gag constructs showed improved oligomerization efficiency as measured by bioluminescence resonance energy transfer in living cells, contributing to increased viral production and efficient activation of the viral protease responsible for virion maturation. The genetically modified Gag represents the next generation lentiviral vector, and should contribute to the success of many lentiviral vector applications.
Asunto(s)
Vectores Genéticos/genética , Lentivirus/genética , Precursores de Proteínas/genética , Transducción Genética/métodos , Antígenos CD8/genética , Antígenos CD8/metabolismo , Ingeniería Genética/métodos , Humanos , Microscopía ConfocalRESUMEN
Heartstring is a useful device. However, the device failure at the time of loading the seal into the delivery device is a troublesome issue. To avoid this problem, we invent a new method using 2 tourniquets made of 5 mm-wide woven Teflon tapes and plastic tubes. Using our method, the loading procedure became easier and more reliable.
Asunto(s)
Puente de Arteria Coronaria/instrumentación , Torniquetes , Anastomosis Quirúrgica/instrumentación , Puente de Arteria Coronaria/métodos , HumanosRESUMEN
OBJECTIVE: The CXCR4/CXCL12 axis appears crucial in the metastasis of bladder cancer. Our aim was to evaluate the potency of the CXCR4 antagonist, 4F-benzoyl-TE14011 (4F-bTE), as an anti-metastatic drug in this disease. In this study, we assessed the ability of 4F-bTE to inhibit tumor cell motility, invasion through extracellular matrix (ECM), matrix metalloproteinase (MMP) secretion and cytoskeletal responses to chemokine. METHODS: To assess the degree to which cells could migrate and invade ECM under various conditions, we used TCCSUP bladder cancer cells in a Boyden chamber system. To monitor actin polymerization, we stained cells on chamber slides with AlexaFluor 594 phalloidin. To measure matrix-metalloproteinase-2 and -9 (MMP) activity, we used gelatin zymography. To assess the effects of the CXCR4 antagonist 4F-bTE on each of the above parameters, we exposed bladder cancer cells either to chemokine CXCL12, alone, or to both CXCL12 and 4F-bTE. We also monitored cells for apoptotic and necrotic changes during drug treatment. RESULTS: The CXCR4 antagonist 4F-bTE markedly decreased CXCL12-induced bladder cancer cell migration and ECM invasion in Boyden chamber assays. The antagonist also blocked chemokine-induced actin polymerization as well as the induction of MMP-2 and MMP-9 in these cells. CONCLUSION: The CXCR4 antagonist 4F-bTE has the potential to inhibit expression of the metastatic phenotype and may provide therapeutic value to patients.
Asunto(s)
Fármacos Anti-VIH/farmacología , Invasividad Neoplásica/patología , Receptores de Interleucina-8B/antagonistas & inhibidores , Neoplasias de la Vejiga Urinaria/patología , Movimiento Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Quimiocinas CXC/fisiología , Quimiotaxis/efectos de los fármacos , Humanos , Técnicas In Vitro , Probabilidad , Sensibilidad y Especificidad , Estadísticas no Paramétricas , Células Tumorales Cultivadas/citologíaRESUMEN
Biodegradable poly D,L-lactic acid (PLA, molecular weight: ca. 5000) microcapsules containing a CXCR4 antagonist (4F-benzoyl-TE14011) were prepared (4F-benzoyl-TE14011-PLA), and their anti-metastatic activity was evaluated in mice. A single subcutaneous administration of 4F-benzoyl-TE14011-PLA significantly reduced the number of colonies formed by pulmonary metastasis of B16-BL6 melanoma cells expressing CXCR4. The same dose of 4F-benzoyl-TE14011 in a single or a series of treatments affected little. The substance 4F-benzoyl-TE14011 dose-dependently suppressed B16-BL6 cell growth. In the cells cultured with SDF-1, a more potent suppression was observed. 4F-Benzoyl-TE14011 was rapidly released from 4F-benzoyl-TE14011-PLA for an initial period, both in vitro and in vivo. A steady release was thereafter observed. Therefore, this drug release profile might contribute to prevention of melanoma metastasis at the steps involving the migration and cell growth. These results also show that a sustained drug release formulation could be a useful drug delivery system for CXCR4 antagonists.
Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/patología , Melanoma Experimental/tratamiento farmacológico , Melanoma Experimental/patología , Péptidos/administración & dosificación , Receptores CXCR4/antagonistas & inhibidores , Animales , Antineoplásicos/administración & dosificación , División Celular/efectos de los fármacos , Línea Celular Tumoral , Preparaciones de Acción Retardada/administración & dosificación , Relación Dosis-Respuesta a Droga , Inyecciones Subcutáneas , Ácido Láctico/química , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/secundario , Masculino , Melanoma Experimental/metabolismo , Melanoma Experimental/secundario , Ratones , Ratones Endogámicos C57BL , Poliésteres , Polímeros/química , Receptores CXCR4/metabolismo , Resultado del TratamientoRESUMEN
The authors have discovered a highly selective CXCR4 antagonist, T22 ([Tyr5,12, Lys7]-polyphemusin II), and its shortened potent analogs, T140 and TC14012, which strongly inhibit the T-cell line-tropic HIV-1 (X4-HIV-1) infection through their specific binding to a chemokine receptor, CXCR4. CXCR4 is a major coreceptor (second receptor) for the entry of X4-HIV-1 into T-cells. These peptides have been found through the structure-activity relationship (SAR) study on tachyplesins and polyphemusins, which function as self-defense peptides of horseshoe crabs with immature immune systems. T140 and TC14012 showed the highest level of anti-HIV activity and antagonism of target cell entry by X4-HIV-1 among all the CXCR4 antagonists that have been reported to date. Additionally, bifunctional anti-HIV agents based on the specific CXCR4 antagonists (T140 analogs)-3'-azido-3'-deoxythymidine (AZT) conjugation have been synthesized and evaluated, since T140 analogs can possibly work as a carrier of AZT targeting T-cells due to their specific affinity for CXCR4 on T-cells. T22 have two disulfide bonds and a Trp residue in the molecule. In connection with this study, novel facile and side-reaction-free methodologies for disulfide bond formation have been established for the increase of the efficiency of SAR studies. Furthermore, the completely stereocontrolled synthetic process for a couple of (E)-alkene dipeptide isosteres starting from L-amino acid has been established in order to facilitate nonpeptidylation studies on peptide-lead candidates. In this review, the authors wish to summarize our recent research on the development of specific antagonists against the HIV second receptor CXCR4, involving studies on the establishment of efficient methodologies for the facile synthesis of peptides and peptide mimetics.
Asunto(s)
Fármacos Anti-VIH , Péptidos Catiónicos Antimicrobianos , Oligopéptidos , Receptores CXCR4/antagonistas & inhibidores , Animales , Fármacos Anti-VIH/síntesis química , Fármacos Anti-VIH/farmacología , Péptidos Catiónicos Antimicrobianos/síntesis química , Péptidos Catiónicos Antimicrobianos/farmacología , Química Orgánica , Quimiocina CXCL12 , Quimiocinas CXC/síntesis química , Cistina , Disulfuros , Oligopéptidos/síntesis química , Oligopéptidos/farmacología , Fenómenos Químicos Orgánicos , Péptidos/síntesis química , Relación Estructura-ActividadRESUMEN
The highly selective CXCR4 antagonist, T-22 ([Tyr5,12,Lys7]-polyphemusin II), and its shortened potent analogs, T-140 and TC-14012, strongly inhibit T-cell line-tropic HIV-1 (X4-HIV-1) infection through their specific binding to a chemokine receptor, CXCR4. These peptides were found through studies of the structure-activity relationships of tachyplesins and polyphemusins, which function as self-defence peptides of horseshoe crab's immature immune systems. T-140 and TC-14012 possess the highest level of anti-HIV activity and antagonism of target cell entry by X4-HIV-1 among all the CXCR4 antagonists that have been reported to date.
Asunto(s)
Fármacos Anti-VIH/síntesis química , Fármacos Anti-VIH/farmacología , Receptores CXCR4/antagonistas & inhibidores , Secuencia de Aminoácidos , Fármacos Anti-VIH/química , Quimiocinas CXC/metabolismo , Humanos , Datos de Secuencia Molecular , Relación Estructura-ActividadRESUMEN
We have previously found that T140, a 14-amino acid residue peptide, inhibits infection of target cells by T cell-line-tropic strains of HIV-1 (X4-HIV-1) through its specific binding to a chemokine receptor, CXCR4. Here, we report synthesis and evaluation of bifunctional anti-HIV compounds, which are composed of T140 analogues and a reverse transcriptase inhibitor, 3'-azido-3'-deoxythymidine (AZT). Novel conjugated analogues have been proved to have the ability for controlled release of AZT in neutral aqueous media as well as mouse and feline sera, and high selectivity indexes (SIs, 50% cytotoxic concentration/50% effective concentration) caused by a synergistic effect of two different regenerating agents. Thus, these bifunctional compounds have several potential advantages. T140 analogues can possibly work as a carrier of AZT targeting T cells due to their specific affinity for CXCR4 on T cells. A synergistic effect by two types of regenerating agents may enable drug dosage to be reduced, and thus it may effectively suppress toxic side effects and the appearance of drug-resistant virus.
Asunto(s)
Fármacos Anti-VIH/síntesis química , Receptores CXCR4/antagonistas & inhibidores , Animales , Fármacos Anti-VIH/química , Fármacos Anti-VIH/farmacología , Gatos , Estabilidad de Medicamentos , VIH-1/efectos de los fármacos , Semivida , Humanos , Sueros Inmunes/metabolismo , Ratones , Receptores CXCR4/química , Células Tumorales Cultivadas , Zidovudina/síntesis química , Zidovudina/química , Zidovudina/farmacologíaRESUMEN
We previously reported a truncated polyphemusin peptide analogue, T140, which efficiently inhibits infection of target cells by T-cell line-tropic strains of HIV-1 (X4-HIV-1) through its specific binding to a chemokine receptor, CXCR4. We have found that T140 is not stable in feline serum due to the cleavage of the C-terminal Arg,(14) indispensable for anti-HIV activity. On the other hand, a C-terminally amidated analogue of T140, TZ14004, has been found to be completely stable in incubation in the serum for 2 days. The C-terminal amide is thought to be needed for stability in serum. However, TZ14004 does not have fairly strong anti-HIV activity, but has relatively strong cytotoxicity, probably due to an increase by +1 charge from total +7 charges of T140. In our previous study, the number of total +6 charges seemed to be a suitable balance between activity and cytotoxicity. In this study, we have conducted a double-L-citrulline (Cit)-scanning study on TZ14004 based on the C-terminally amidated form in due consideration of the total net charges in the whole molecule to find novel effective CXCR4 inhibitors, TN14003 ([Cit(6)]-T140 with the C-terminal amide) and TC14012 ([Cit(6), D-Cit(8)]-T140 with the C-terminal amide), which possess high selectivity indexes (SIs) and complete stability in feline serum.
Asunto(s)
Fármacos Anti-VIH/química , Fármacos Anti-VIH/farmacología , Citrulina/química , VIH-1/efectos de los fármacos , Receptores CXCR4/antagonistas & inhibidores , Animales , Fármacos Anti-VIH/sangre , Fármacos Anti-VIH/toxicidad , Gatos , Supervivencia Celular/efectos de los fármacos , Dicroismo Circular , Estabilidad de Medicamentos , Humanos , Concentración 50 Inhibidora , Oligopéptidos/química , Oligopéptidos/farmacología , Péptidos/síntesis química , Péptidos/química , Péptidos/farmacologíaRESUMEN
The chemokine receptors CXCR4 and CCR5 are considered to be potential targets for the inhibition of HIV-1 replication. We found that the synthetic peptides T134 and T140 (see text for full names) inhibited X4 HIV-1 infection with selectivity and low toxicity because they acted as CXCR4 antagonists. However, high concentrations of T134, T140, and ALX40-4C (see text for full name) increased the expression of CCR5 and R5 HIV-1 infection, as did stromal cell-derived factor 1 (SDF-1). In contrast to CXCR4 antagonists and SDF-1, viral monocyte inflammatory protein (vMIP) II inhibited not only anti-CXCR4 monoclonal antibody (MAb) but also inhibited anti-CCR5 MAb binding to human peripheral blood mononuclear cells, and inhibited both X4 and R5 HIV-1 strains. T134, T140, ALX40-4C, and SDF-1 increased viral transcription in the treated cells. In addition, ALX40-4C and SDF-1 also increased nuclear transcription factor (NF)-kappaB. However, the mechanisms of action of T134 and T140 are different from those of clinically used anti-HIV drugs. Thus, synergistic activities were observed in the concomitant treatment with T134 and reverse transcriptase inhibitors or protease inhibitors. Our findings, presented here, are noteworthy in regard to the potential clinical use of these agents as drugs for the treatment of AIDS.
Asunto(s)
Fármacos Anti-VIH/farmacología , Linfocitos T CD4-Positivos/efectos de los fármacos , Quimiocinas CXC/farmacología , Quimiocinas/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , VIH-1/fisiología , Oligopéptidos/farmacología , Receptores CCR5/biosíntesis , Receptores CXCR4/antagonistas & inhibidores , Replicación Viral/efectos de los fármacos , Animales , Anticuerpos Monoclonales/farmacología , Bencilaminas , Antígenos CD4/biosíntesis , Antígenos CD4/genética , Linfocitos T CD4-Positivos/metabolismo , Linfocitos T CD4-Positivos/virología , Células COS , Quimiocina CXCL12 , Chlorocebus aethiops , Ciclamas , Sinergismo Farmacológico , Duplicado del Terminal Largo de VIH , Compuestos Heterocíclicos/farmacología , Humanos , Metionina/análogos & derivados , Metionina/farmacología , Fragmentos de Péptidos/farmacología , Receptores CCR5/genética , Transfección , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/metabolismo , Células Tumorales Cultivadas/virología , Zidovudina/farmacologíaRESUMEN
The chemokine receptors CXCR4 and CCR5 are considered to be potential targets for the inhibition of HIV-1 replication. We have reported that T134 and T140 inhibited X4 HIV-1 infection specifically because they acted as CXCR4 antagonists. In the present study, we have generated a T134-resistant virus (trHIV-1(NL4-3)) in a cell culture with gradually increasing concentrations of the compound. The EC(50) of T134 against trHIV-1(NL4-3) recovered after 145 passages was 15 times greater than that against wild-type HIV-1(NL4-3). This adapted virus was resistant to other CXCR4 antagonists, T140, AMD3100, and ALX40-4C, and SDF-1; from 10 to 145 times greater than that against wild-type HIV-1(NL4-3). On the other hand, T134, T140, and ALX40-4C were still active against AMD3100-resistant viruses (arHIV-1(018A)). The trHIV-1(NL4-3) contained the following mutations in the V3 loop of gp120: N269K, Q278T, R279K, A284V, F285L, V286Y, I288T, K290E, N293D, M294I, and Q296K; an insertion of T at 290; and Delta274-275 (SI). In addition, many other mutations were recognized in the V1, V2, and V4 domains. Thus, resistance to T134 may be the consequence of amino acid substitutions in the envelope glycoprotein of X4 HIV-1. The trHIV-1(NL4-3) could not utilize CCR5 as an HIV infection coreceptor, although many amino acid substitutions were recognized. The trHIV-1(NL4-3) acquired resistance to vMIP II, which could inhibit both X4 and R5 HIV-1 infection. However, neither the ligands of CCR5, RANTES, and MIP-1alpha, nor a CCR5 low molecular antagonist, TAK-779, were able to influence the infection of trHIV-1(NL4-3). Those results indicated that alternation of coreceptor usage of trHIV-1(NL4-3) was not induced.
Asunto(s)
Fármacos Anti-VIH/farmacología , Infecciones por VIH/tratamiento farmacológico , VIH-1/genética , Oligopéptidos/farmacología , Receptores CCR5/efectos de los fármacos , Receptores CXCR4/efectos de los fármacos , Secuencia de Aminoácidos , Fármacos Anti-VIH/uso terapéutico , Secuencia de Bases , Células Cultivadas , Resistencia a Medicamentos , VIH-1/química , VIH-1/efectos de los fármacos , Datos de Secuencia Molecular , Oligopéptidos/uso terapéutico , Replicación Viral/efectos de los fármacosRESUMEN
We report the solution structure of T140, a truncated polyphemusin peptide analogue that efficiently inhibits infection of target cells by T-cell line-tropic strains of HIV-1 through its specific binding to a chemokine receptor, CXCR4. Nuclear magnetic resonance analysis and molecular dynamic calculations revealed that T140 has a rigidly structured conformation constituted by an antiparallel beta-sheet and a type II' beta-turn. A protuberance is formed on one side of the beta-sheet by the side-chain functional groups of the three amino acid residues (L-3-(2-naphthyl)alanine, Tyr5 and Arg14), each of which is indispensable for strong anti-HIV activity. These findings provide a rationale to dissect the structural basis for the ability of this compound to block the interaction between CXCR4 and envelope glycoproteins from T-tropic strains of HIV-1.
Asunto(s)
Fármacos Anti-VIH/química , Oligopéptidos/química , Receptores CXCR4/antagonistas & inhibidores , Secuencia de Aminoácidos , Fármacos Anti-VIH/farmacología , Simulación por Computador , Modelos Moleculares , Conformación Molecular , Resonancia Magnética Nuclear Biomolecular , Oligopéptidos/farmacología , Estructura Secundaria de Proteína , Relación Estructura-ActividadRESUMEN
A polyphemusin peptide analogue, T22 ([Tyr(5,12), Lys7]-polyphemusin II), and its shortened potent analogues, T134 (des-[Cys(8,13), Tyr(9,12)]-[D-Lys10, Pro11, L-citrulline16]-T22 without C-terminal amide) and T140 [[L-3-(2-naphthyl)alanine3]-T134], strongly inhibit the T-cell line-tropic (T-tropic) HIV-1 infection through their specific binding to a chemokine receptor, CXCR4. T22 is an extremely basic peptide possessing five Arg and three Lys residues in the molecule. In our previous study, we found that there is an apparent correlation in the T22-related peptides between the number of total positive charges and anti-HIV activity or cytotoxicity. Here, we have conducted the conventional Ala-scanning study in order to define the anti-HIV activity pharmacophore of T140 (the strongest analogue among our compounds) and identified four indispensable amino acid residues (Arg2, Nal3, Tyr5, and Arg14). Based on this result, a series of L-citrulline (Cit)-substituted analogues of T140 with decreased net positive charges have been synthesized and evaluated in terms of anti-HIV activity and cytotoxicity. As a result, novel effective inhibitors, TC14003 and TC14005, possessing higher selectivity indexes (SIs, 50% cytotoxic concentration/50% effective concentration) than that of T140 have been developed.
Asunto(s)
Fármacos Anti-VIH/farmacología , VIH-1/efectos de los fármacos , Oligopéptidos/farmacología , Receptores CXCR4/antagonistas & inhibidores , Secuencia de Aminoácidos , Fármacos Anti-VIH/química , Línea Celular , Dicroismo Circular , Humanos , Pruebas de Sensibilidad Microbiana , Datos de Secuencia Molecular , Oligopéptidos/químicaRESUMEN
Specificities of three mouse major histocompatibility complex (MHC) class I molecules, Kb, Db, and Ld, were analyzed by positional scanning using combinatorial peptide libraries. The result of the analysis was used to create a scoring program to predict MHC-binding peptides in proteins. The capacity of the scoring was then challenged with a number of peptides by comparing the prediction with the experimental binding. The score and the experimental binding exhibited a linear correlation but with substantial deviations of data points. Statistically, for approximately 80% of randomly chosen peptides, MHC-binding capacity could be predicted within one log concentration of peptides for a half-maximal binding. Known cytotoxic T-lymphocyte epitope peptides could be predicted, with a few exceptions. In addition, frequent findings of MHC-binding peptides with incomplete or no anchor amino acid(s) suggested a substantial bias introduced by natural antigen processing in peptide selection by MHC class I molecules.
Asunto(s)
Presentación de Antígeno/inmunología , Antígenos de Histocompatibilidad Clase I/inmunología , Complejo Mayor de Histocompatibilidad/inmunología , Biblioteca de Péptidos , Péptidos/inmunología , Animales , Automatización , Sitios de Unión , Línea Celular , Epítopos de Linfocito T/inmunología , Antígenos H-2/inmunología , Antígeno de Histocompatibilidad H-2D , Antígenos de Histocompatibilidad Clase I/metabolismo , Ratones , Péptidos/metabolismoRESUMEN
In previous work, we have obtained potent protein kinase C (PK-C) ligands with low-namomolar binding affinities by constructing diacylglycerol (DAG) mimetics in which the sn-2 carbonyl of DAG was constrained into a lactone ring. An additional structural element that helped achieve high binding affinity was the presence of branched acyl or alpha-alkylidene chains. In the present study, the effects of similarly branched chains on a different lactone system, where the lactone carbonyl is now equivalent to the sn-1 carbonyl of DAG, are investigated. In this new lactone template, the two chiral centers must have the S-configuration for enzyme recognition. As with the sn-2 DAG lactones, the branched chains were designed to optimize van der Waals contacts with a group of conserved hydrophobic amino acids located on the rim of the C1 domain of PK-C. The acyl and alpha-alkylidene chains were also designed to be lipophilically equivalent (8 carbons each). Eight new compounds (7-14) representing all possible combinations of linear and branched acyl and alpha-alkylidene were synthesized and evaluated. The sn-1 DAG lactones were less effective as PK-C ligands than the sn-2 DAG lactones despite having a similar array of linear or branched acyl and alpha-alkylidene chains
Asunto(s)
Diglicéridos/síntesis química , Lactonas/síntesis química , Proteína Quinasa C/metabolismo , Diglicéridos/química , Diglicéridos/metabolismo , Isoenzimas/metabolismo , Lactonas/química , Lactonas/metabolismo , Ligandos , Imitación Molecular , Unión Proteica , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
A new practical strategy has been developed for the synthesis of long-chain phosphopeptide. Both the 2-chlorobenzyloxycarbonyl (CIZ) group for Lys and methyl (Me) for phosphoamino acids remained intact, while other commonly used side-chain protecting groups were cleaved quantitatively, during the reaction using a highly acidic trifluoromethanesulfonic acid (TFMSA)-based reagent system (High TFMSA: TFMSA-TFA-m-cresol=1:9:1, v/v). Selective deprotection of the CIZ and Me group-containing protected phosphopeptide resin with the High TFMSA gave a partially protected phosphopeptide fragment suitable for thioester-mediated fragment condensation. A deprotection protocol of the 9-fluorenylmethyloxycarbonyl (Fmoc) group, which evades significant side reaction toward the protected phosphoamino acid, was also developed. These two new findings enabled us to synthesize long-chain phosphopeptide via thioester-mediated fragment condensation.
Asunto(s)
Fosfopéptidos/síntesis química , Secuencia de Aminoácidos , Ésteres , Datos de Secuencia Molecular , Fosfopéptidos/químicaRESUMEN
Stereoselective syntheses of all four stereoisomers of CF(2)-substituted nonhydrolyzable phosphothreonine derivatives (33, 39, and their enantiomers) and their incorporation into peptides are described herein. Key to the synthesis of these amino acids was construction of secondary phosphate-mimicking difluoromethylphosphonate units along with generation of two stereocenters. The former was achieved using a Cu(I)-mediated cross-coupling reaction of BrZnCF(2)P(O)(OEt)(2) (8) and beta-iodo-alpha,beta-unsaturated ester 12, with stereochemistry of both alpha- and beta-stereocenters being established using bornane-10,2-sultam as a chiral auxiliary. Diastereoselective hydrogenation of a chiral alpha,beta-unsaturated acylsultam (for the beta-center) (e.g., 16a) and subsequent stereoselective bromination (for the alpha-center of the threo derivative) or amination (for the alpha-center of erythro (allo) derivative) were utilized. Transesterification of the bromide to the benzyl ester followed by azide displacement of the halogen, then reduction of the resulting azide, followed by Boc-protection and finally removal of the benzyl group, afforded protected both L- and D-phosphothreonine mimetics (39 and its enantiomer). On the other hand, protected both L- and D-allo-phosphothreonine mimetics (33 and its enantiomer) were synthesized via transesterification of the above-mentioned amination product, followed by hydrogenolytic removal of the benzyl group. Key to utilization of these amino acid analogues in peptide synthesis was removal of ethyl protection from the difluoromethylphosphonate moiety. A two-step deprotection methodology, consisting of a combination of a first-step reagent [0.3 M BSTFA-TBAI in CH(2)Cl(2), BF(3).Et(2)O] followed by a second-step reagent [1 M TMSOTf-thioanisole in TFA, m-cresol, EDT] was developed for use in solid-phase protocols. A 12-residue Cdc (cell division cycle) 2-peptide 41, possessing two nonhydrolyzable phosphoamino acid mimetics (F(2)Pmab 6 and F(2)Pmp 4), was subjected to this deprotection procedure and was obtained in 25% yield based on the protected resin. The present synthetic method affords nonhydrolyzable phosphoamino acid mimetics-containing peptides in high yield without accompanying side reactions.
Asunto(s)
Imitación Molecular , Péptidos/síntesis química , Fosfotreonina , Treonina/análogos & derivados , Treonina/síntesis química , Indicadores y Reactivos , IsomerismoRESUMEN
A 70-year-old man with NIDDM was diagnosed as having renovascular hypertension (RVH), based on a stenosis of the ostial portion of the left renal artery with markedly elevated plasma renin activity (PRA) in both the left renal vein and the peripheral blood, and positive captopril tests. After percutaneous transluminal renal angioplasty (PTRA), his blood pressure (BP) and PRA normalized. However, since restenosis occurred three months later, stent therapy was applied, and consequently BP and PRA normalized immediately after this procedure. During the one-year follow-up, side effects have not been noted. We propose that stent therapy may be feasible for ostial renal artery stenosis in elderly diabetic patients.
Asunto(s)
Diabetes Mellitus Tipo 2/complicaciones , Hipertensión Renovascular/etiología , Hipertensión Renovascular/cirugía , Stents , Factores de Edad , Anciano , Humanos , MasculinoRESUMEN
Lipopolysaccharides of gram-negative bacteria are potent activators of B cells, dendritic cells and monocytes/macrophages. We have investigated the use of LPS-activated spleen cells as antigen-presenting cells to induce CD8+ cytotoxic T lymphocytes in vivo that are reactive to MHC class I binding peptides. Compared with resting spleen cells, CTL induction was more efficient and less variable for different peptides with LPS-activated spleen cells. Cytotoxic responses were specific for the immunized peptides and contained high affinity CD8+ T cells. The removal of dendritic cells and monocytes/macrophages by Sephadex G10 column did not show profound effects on CTL induction, indicating that B-cell blasts were largely responsible. This easily accessible method should facilitate the screening of MHC class I binding peptides to determine whether or not the host's T-cell repertoire contains reactive T cells.
Asunto(s)
Lipopolisacáridos/inmunología , Activación de Linfocitos , Péptidos/inmunología , Bazo/inmunología , Linfocitos T Citotóxicos/inmunología , Animales , Antígenos de Histocompatibilidad Clase I/inmunología , Antígenos de Histocompatibilidad Clase I/metabolismo , Inmunización , Ratones , Ratones Endogámicos C57BL , Bazo/citologíaRESUMEN
We recently reported that a cationic peptide, T22 ([Tyr(5,12), Lys(7)]-polyphemusin II), specifically inhibits human immunodeficiency virus type 1 (HIV-1) infection mediated by CXCR4 (T. Murakami et al., J. Exp. Med. 186:1389-1393, 1997). Here we demonstrate that T22 effectively inhibits replication of T-tropic HIV-1, including primary isolates, but not of non-T-tropic strains. By using a panel of chimeric viruses between T- and M-tropic HIV-1 strains, viral determinants for T22 susceptibility were mapped to the V3 loop region of gp120. T22 bound to CXCR4 and interfered with stromal-cell-derived factor-1alpha-CXCR4 interactions in a competitive manner. Blocking of anti-CXCR4 monoclonal antibodies by T22 suggested that the peptide interacts with the N terminus and two of the extracellular loops of CXCR4. Furthermore, the inhibition of cell-cell fusion in cells expressing CXCR4/CXCR2 chimeric receptors suggested that determinants for sensitivity of CXCR4 to T22 include the three extracellular loops of the coreceptor.